Evidence map›Paper›PMID 35118493›Full record

ArticleBioscience reports2022

XSSJS inhibits hepatic fibrosis by promoting the miR-29b-3p/VEGFA axis in vitro and in vivo.

Tianyao Zhang, Yu Yang, Baojia Wang, Long Wang, Dong Wang, Ning Cao, Jinyu Shi

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tianyao ZhangDepartment of Fundamental Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID 0000-0001-9633-3245
Yu YangDepartment of Fundamental Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Baojia WangDepartment of Fundamental Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID 0000-0002-3148-5595
Long WangDepartment of Fundamental Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Dong WangDepartment of Fundamental Medical Science, Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China.
Ning CaoDepartment of Fundamental Medical Science, Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China.
Jinyu ShiDepartment of Fundamental Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Chengdu University of Traditional Chinese Medicine · CNShaanxi University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic pathological angiogenesis (HPA) is the key event of hepatic fibrosis (HF). Xueshisanjia powder (XSSJS), a Chinese herbal compound, is beneficial for alleviating pathological angiogenesis of hepatic tissue. The present study attempts to reveal the effect and mechanism of XSSJS via regulating miR-29b-3p/VEGFA axis against pathological angiogenesis in HF. In in vitro model, human embryonic kidney 293T cells were transfected with miR-29b-3p mimics, whereby the expression of miR-29b-3p was tested by real-time quantitative polymerase chain reaction (RT-qPCR), ensued by Luciferase assay determining the relationship between miR-29b-3p and vascular endothelial cell growth factor A (VEGFA). In addition, miR-29b-3p mimic transfected into the activated hepatic stellate cell T6 (HSC-T6). The Cell-Counting-Kit 8 (CCK8) and 5-Bromodeoxyuridine (BrdU) staining were first utilized to detect the antiproliferative efficiency of XSSJS following the XSSJS compound serum intervention, and then used to observe the expression of transforming growth factor-β (TGF-β), VEGFA, platelet-derived growth factor (PDGF) via RT-PCR, Western blot (WB), and Immunofluorescence (IF) methods. During the in vivo model, XSSJS with boil-free granules were fed to Wistar rats with liver fibrosis caused by intraperitoneal injection of pig serum followed by the transfection of miR-29b-3p adeno-associated virus (AAV). Hematoxylin-Eosin (HE) staining was used for histopathology assessment. The expression of miR-29b-3p, VEGFA, PDGF, TGF-β have been investigated in liver tissue using RT-PCR, WB, IF. The results verified that XSSJS could up-regulate miR-29b-3p and suppress the expression of VEGFA, PDGA, and TGF-β. In mechanism, miR-29b-3p primarily targeted the 3'UTR of VEGFA. In conclusion, XSSJS could modulate miR-29b-3p/VEGFA axis to inhibit the pathological angiogenesis of HF.

Indexed as

MicroRNAsAnimalsCell ProliferationLiver CirrhosisNeovascularization, PathologicPlatelet-Derived Growth FactorRatsRats, WistarSwineTransforming Growth Factor betaVascular Endothelial Growth Factor AMicroRNAsPlatelet-Derived Growth FactorTransforming Growth Factor betaVascular Endothelial Growth Factor Avascular endothelial growth factor A, rathepatic fibrosis(HF)miR-29b-3ppathological angiogensisVEGFAXueshisanjiasan (XSSJS)

Identifiers

PMID35118493
PMCPMC8881647
OpenAlexW4210722034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.